BioMarin Pharmaceutical Inc.
BioMarin develops and commercializes therapies for rare diseases. Products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme. The company also develops Roctavian for severe hemophilia A. It serves specialty pharmacies, hospitals, and government agencies in the US, Europe, Latin America, and internationally.
Overview
Strengths
- Valued below its Biotechnology peers: P/FCF 15.0x vs. a median of 20.2x.
- Consistent growth: revenue has compounded at 11.6% a year over 5 years, rising in 4 of them.
- Net cash balance sheet: cash exceeds total debt.
Weaknesses
- Our discounted cash flow target price (42.27 USD) is 25% below the current price.
- Unstable profitability: operating margin ranged from -5% to 17% over the last 6 years, with operating losses in 2 of them.
- Valued at a premium to its Biotechnology peers: P/E 30.9x vs. a median of 19.2x.
Key Financial Data